Quarterly ResultMay 7, 2026, 04:23 PM
OmniAb Q1 Revenue Jumps to $14.4M; Raises 2026 Guidance
AI Summary
OmniAb, Inc. reported strong financial results for the first quarter of 2026, with revenue surging to $14.4 million, a substantial increase from $4.2 million in the prior year. The company also significantly reduced its net loss to $7.7 million, or $0.06 per share, compared to $18.2 million, or $0.17 per share, in Q1 2025. Driven by this momentum, OmniAb raised its full-year 2026 revenue guidance and increased its year-end cash and cash equivalents outlook, while also highlighting advancements in multiple partnered clinical programs.
Key Highlights
- OmniAb's Q1 2026 revenue increased to $14.4 million, up from $4.2 million in Q1 2025.
- Net loss for Q1 2026 significantly reduced to $7.7 million ($0.06 per share) from $18.2 million ($0.17 per share) in Q1 2025.
- The company raised its 2026 revenue guidance to a range of $28 million to $33 million, up from $25 million to $30 million.
- Year-end 2026 cash and cash equivalents guidance increased to $33 million to $38 million.
- Research and development expense decreased to $9.6 million in Q1 2026 from $12.6 million in Q1 2025.
- General and administrative expense decreased to $6.6 million in Q1 2026 from $7.9 million in Q1 2025.
- As of March 31, 2026, OmniAb had 107 active partners and 409 active programs.
- A registrational trial for partnered program IMVT-1402 is fully enrolled, with topline data expected in H2 2026.